BriaCell develops ovarian cancer immunotherapy candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. WDC
2. DECK
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. TSCO
9. WCN
10. KNSL

Go back to BriaCell develops ovarian cancer immunotherapy candidate

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

May 15, 2026 7:30 AM EDT

BriaCell expands push in womens health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCells next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:... More